all report title image

SULFADIAZINE SODIUM INJECTION MARKET ANALYSIS

Sulfadiazine Sodium Injection Market, by Product Type (20mg/mL, 40mg/mL, others), by Patient Type (Human, and Animal), By Indication (Toxoplasmosis, Acute Otitis Media (AOM), Chancroid, Chlamydial Infections, Haemophilus Influenzae Infections, Malaria, Neisseria Meningitides Infections, Plague, Urinary Tract Infections), by End User (Hospitals, Clinics, Medical Centers, and Veterinary), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI2313
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Sulfadiazine Sodium Injection Market– Restraint

Over the years, bacterial pathogens acquired resistance to sulfonamide class of antibiotics, due to mutations in pre-existing DNA, or by acquisition of antibiotic resistance genes (ARGs), which is expected to hinder growth of the sulfachloropyridazine sodium market. For instance, according to Centers for Disease Control and Prevention (CDC), in the U.S. doctors and emergency departments, prescribe at least 47 million antibiotic prescriptions each year, which are unnecessary. These are creating spread of antibiotics resistance, which might lead to severe consequences.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.